FINWIRES · TerminalLIVE
FINWIRES

Smith & Nephew Says CARTIHEAL Implant Shows Compelling 5-Year Outcomes

By

Smith & Nephew (SNN) said Tuesday that new data from a clinical trial show "compelling" long-term results for its CARTIHEAL AGILI-C cartilage repair implant.

The company said the study found the implant outperformed standard surgical care across all measured time points up to five years, adding that the patients treated with the implant reported better pain relief and improved quality of life over the five-year period. They also showed greater improvements in daily activities, sports, and recreation at two, four, and five years after treatment, according to a statement.

The study also found similar outcomes in patients with and without osteoarthritis, the company added.

The implant recently received a category one current procedural terminology code for procedures that will take effect on Jan. 1, 2027, the company said.

Shares of Smith & Nephew were down nearly 3.4% in the session.

Price: $33.04, Change: $-1.17, Percent Change: -3.42%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB